Page last updated: 2024-08-23

cetylpyridinium chloride anhydrous and Multiple Myeloma

cetylpyridinium chloride anhydrous has been researched along with Multiple Myeloma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shaughnessy, JD1
Alder, H; Aqeilan, RI; Boccadoro, M; Croce, CM; Drandi, D; Garzon, R; Hagan, JP; Kuehl, M; Ladetto, M; Munker, R; Palumbo, A; Palumbo, T; Pichiorri, F; Suh, SS; Taccioli, C; Volinia, S; Zanesi, N1
Erickson, LD; Gleeson, MW; Noelle, RJ; O'Connor, BP1
Burmester, GR; Egerer, K; Feist, E; Fleissner, C; Heider, U; Jakob, C; Kaiser, M; Kleeberg, L; Kloetzel, PM; Kuckelkorn, U; Liebisch, P; Sezer, O; Sterz, J; Türkmen, S; Zavrski, I1
Barlogie, B; Chen, LC; Crowley, J; Dhodapkar, MV; Durie, B; Gure, AO; Jagannath, S; Kukreja, A; Matthews, P; Mazumder, A; Ritter, G; Scanlan, MJ; Shaughnessy, JD; Simpson, AJ; Spisek, R; Vesole, D; Zebroski, HA1

Reviews

1 review(s) available for cetylpyridinium chloride anhydrous and Multiple Myeloma

ArticleYear
The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.
    Immunological reviews, 2003, Volume: 194

    Topics: Animals; Antibody Formation; Cell Differentiation; Disease; Health; Humans; Multiple Myeloma; Plasma Cells

2003

Other Studies

4 other study(ies) available for cetylpyridinium chloride anhydrous and Multiple Myeloma

ArticleYear
Cancer: An unexpected addiction.
    Nature, 2008, Jul-10, Volume: 454, Issue:7201

    Topics: Animals; B-Lymphocytes; Cell Survival; Cell Transformation, Neoplastic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, myc; Health; Humans; Interferon Regulatory Factors; Multiple Myeloma; Proto-Oncogene Proteins c-myc

2008
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.
    Proceedings of the National Academy of Sciences of the United States of America, 2008, Sep-02, Volume: 105, Issue:35

    Topics: Animals; Apoptosis Regulatory Proteins; Base Sequence; Bcl-2-Like Protein 11; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Health; Humans; Membrane Proteins; Mice; Mice, Nude; MicroRNAs; Molecular Sequence Data; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; p300-CBP Transcription Factors; Plasma Cells; Proto-Oncogene Proteins; Receptors, Interleukin-6; Repressor Proteins; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins; Tumor Suppressor Protein p53; Up-Regulation

2008
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
    Blood, 2007, Mar-01, Volume: 109, Issue:5

    Topics: Female; Health; Humans; Male; Multiple Myeloma; Prognosis; Proteasome Endopeptidase Complex; Protein Transport; Survival Rate

2007
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
    The Journal of experimental medicine, 2007, Apr-16, Volume: 204, Issue:4

    Topics: Biomarkers; Cell Proliferation; Cells, Cultured; Disease Progression; Embryonic Stem Cells; Health; HMGB Proteins; Humans; Immunoglobulin G; Multiple Myeloma; Neoplasms; Paraproteinemias; SOXB1 Transcription Factors; T-Lymphocytes; Transcription Factors; Treatment Outcome

2007